Clinical trials: Gut
Gynecologic Cancer, Immunotherapy
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation.
- Conditions
- Gynecologic Cancer, Immunotherapy, Gut Microbiome
- Trial name
- NCT04957511
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Viome
Short Bowel Syndrome, Short Gut Syndrome
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
MP-101 will be evaluated in this study to see if it is safe and tolerable.
- Conditions
- Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Gut
- Trial name
- NCT02246816
- Testing
- 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
- Where
- 5 sites in United States
- Sponsor
- Marathon Pharmaceuticals, LLC
Celiac Disease
Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.
- Trial name
- NCT01917630
- Testing
- ALV003
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 500 people
- Sponsor
- Alvine Pharmaceuticals Inc.
Colorectal Cancer
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00022698
- Testing
- Capecitabine, Irinotecan
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Screening Colonoscopy for Low Risk Subjects
First in Man Aer-O-Scope
A single center study intended to evaluate the Aer-O-Scope Colonoscope System.
- Trial name
- NCT02102412
- Testing
- screening colonoscopy
- Where
- Croatia
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- GI View Ltd.
Growth, Tolerance
Human Milk Oligosaccharides (HMOs) Post-market Study on Infants
Human milk oligosaccharides (HMOs) represent the third largest solid component of breast milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL, LNnT).
- Conditions
- Growth, Tolerance, Adverse Event, Disorder of Intestine
- Trial name
- NEHMO (NCT04055363)
- Testing
- HMO-supplemented infant formula
- Where
- 6 sites in Spain
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Systemic Lupus Erythematosus, Arthritic Psoriasis
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165…
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03254784
- Testing
- BMS-986165 Capsule, BMS-986165 Tablet
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Colorectal Neoplasms
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
The main objectives of this study are to establish a safe, tolerable and active dose of 1018 ISS administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer.
- Trial name
- NCT00403052
- Testing
- 1018 ISS immunostimulatory oligonucleotide
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dynavax Technologies Corporation
Rectal Cancer, Anastomotic Leak
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
LifeSeal™ Kit, surgical sealant designed for staple-line reinforcement that is applied over the anastomotic line to prevent bowel content leakage until full physiological function is restored.
- Trial name
- NCT02907385
- Testing
- LifeSeal™ Kit
- Where
- 39 sites in United States, Belgium and 5 more
- Volunteers
- 736 people
- Sponsor
- LifeBond Ltd.
Urinary Tract Infections, Infectious Diarrhea
Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
The purpose of this study is to assess the feasibility of TrueLoo™, an Internet-connected smart toilet seat, in accurately monitoring and logging bowel movements and urinations of residents in senior living facilities across…
- Conditions
- Urinary Tract Infections, Infectious Diarrhea, Clostridium Difficile Infection, Gastrointestinal Disease
- Trial name
- NCT05008640
- Testing
- TrueLoo™
- Where
- 6 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Toi Labs, Inc.
Colonic Diseases
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Night Procedure
The purpose of this study is to evaluate the effect of the night procedure in regards to colon cleansing level and capsule excretion rate.
- Trial name
- NCT00951587
- Testing
- PillCam™ (Capsule Endoscopy)
- Where
- 2 sites in Germany
- Volunteers
- 49 people
- Sponsor
- Medtronic - MITG
Lymphocytic Colitis
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of lymphocytic colitis.
- Trial name
- NCT01209208
- Testing
- Budesonide, Mesalamine
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- Dr. Falk Pharma GmbH
Diarrhea-predominant Irritable Bowel Syndrome
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.
- Trial name
- NCT01358708
- Testing
- LACTEOL® 340 mg
- Where
- 8 sites in France, Germany
- Volunteers
- 26 people
- Sponsor
- Forest Laboratories
Colorectal Cancer, Colo-rectal Cancer
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01
The primary objective of this sub-study is to obtain de-identified, clinically characterized, stool specimens from subjects with untreated solid tumors for research use in the development and validation of a stool-based test for…
- Conditions
- Colorectal Cancer, Colo-rectal Cancer, Cancer
- Trial name
- NCT04473625
- Testing
- Stool Sample Collection
- Where
- 12 sites in United States
- Volunteers
- 291 people
- Sponsor
- Exact Sciences Corporation
Low Anterior Resection, Proctosigmoid Resection
Radial Reload Open LAR Case Series
The purpose of this research study is to evaluate the safety and feasibility of the Radial Reload Stapler during open LAR for rectal cancer. The surgeon will complete questionnaires relating to the function of the device.
- Conditions
- Low Anterior Resection, Proctosigmoid Resection, Rectal Cancer
- Trial name
- NCT01717014
- Testing
- Covidien Radial Reload Stapler with Tri-Staple Technology
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Medtronic - MITG
Metastatic Breast Cancer, Metastatic Colon Cancer
Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Metastatic Colon Cancer, Metastatic Prostate Cancer
- Trial name
- NCT02655952
- Testing
- Foxy-5
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 17 people
- Sponsor
- WntResearch AB
Ulcerative Colitis
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
This is a multi-center, randomized, parallel arm, double-blind study with approximately 750 participants with moderately to severely active Colitis Ulcerosa randomized to receive either PB016 or Entyvio®
- Trial name
- UCESIVE (NCT05771155)
- Testing
- Intravenous (IV) infusions
- Where
- Georgia
- Volunteers
- 750 people
- Sponsor
- Polpharma Biologics S.A.
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Crohn's Disease
Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
The objectives of this study were to assess the safety and tolerability of LDP-02 in patients with active Crohn's disease who were not receiving corticosteroids or immunosuppressives, to assess the ability of LDP-02 to reduce…
- Trial name
- NCT00655135
- Testing
- LDP-02
- Volunteers
- 185 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Short Bowel Syndrome
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
The main aims of the study are to check for side effects from teduglutide. Participants will receive a daily injection of teduglutide just under the skin (subcutaneous) for 24 weeks. Then they are followed up for another 4 weeks.
- Trial name
- NCT05027308
- Testing
- Teduglutide
- Where
- 6 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.